Please ensure Javascript is enabled for purposes of website accessibility

Why Dicerna Rocketed Higher Today

By Brian Orelli, PhD – Updated Apr 20, 2018 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are happy the biotech ended a lawsuit hanging over its head.

What

Dicerna Pharmaceuticals (DRNA) is up 18.6% at 3:31 p.m. EDT after announcing that it settled a trade secrets lawsuit with Alnylam Pharmaceuticals (ALNY 2.26%), which is up 1.3% itself.

Call it a win-win settlement.

So what

Both companies are developing RNA interference drugs that seek to knock down protein levels by targeting RNA, which is the intermediary between genes on DNA and the protein the genes encode for. Alnylam claimed that Dicerna was interfering with its trade secrets. Dicerna countered, claiming anti-competitive practices.

To end both sides of the lawsuit, Dicerna agreed to pay Alnylam an upfront fee of $2 million plus 983,208 shares of Dicerna common stock, which are now worth a little under $12 million thanks to today's jump in the price. Dicerna will also pay Alnylam another $13 million over the next four years. The timing of those additional payments will be determined by when Dicerna receives revenue from future partnerships it sets up for its GalXC technology.

Dicerna ended 2017 with just under $114 million, so the $2 million upfront fee won't be too bad. And linking the remaining payments to future partnerships will hopefully result in payments when the company has cash coming in. The extra shares will dilute current shareholders a little, but with around 25 million shares outstanding, it's a small price to pay for not having the lawsuit hanging over the company's head.

Outside of a courthouse

Image source: Getty Images.

Now what

Dicerna can now refocus on its pipeline, including its phase 1 drug DCR-PHXC, which treats primary hyperoxaluria, although it won't be able completely forget about its lawsuit sparing partner, because Alnylam also has a hyperoxaluria drug, lumasiran, which is ready to go into phase 3 development later this year.

Alnylam's longtime development partner, Sanofi (SNY 2.37%), recently passed on its option to license lumasiran, but it's hard to know if that's good or bad news for Dicerna. It could signal that Sanofi is worried that DCR-PHXC is superior, which would obviously be good news. Or Sanofi might think that primary hyperoxaluria isn't a disease worth pursuing, which would seem to be bad news. And of course, there are a lot of potentially neutral reasons for Sanofi to pass, including that it's just more interested in using the options from the development deal on other drugs Alnylam is developing.

Investors won't have to wait too long to get a first look at how DCR-PHXC stacks up to the competition; proof-of-concept data for DCR-PHXC is due in the second half of this year.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dicerna Pharmaceuticals, Inc. Stock Quote
Dicerna Pharmaceuticals, Inc.
DRNA
Sanofi Stock Quote
Sanofi
SNY
$40.12 (2.37%) $0.93
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$201.24 (2.26%) $4.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.